Nuclide Tx and pharmAI announce strategic collaboration

Nuclide Therapeutics Ltd (NTx) and PharmAI GmbH have entered into a strategic collaboration to identify and advance novel small-molecule radiotheranostic candidates. The programme will combine PharmAI’s DiscoveryEngine platform with NTx’s expertise in theranostic design and clinical translation. The collaboration aims to expand NTx’s pipeline beyond its lead programme.

About Nuclide Therapeutics

Nuclide Therapeutics Ltd (NTx) is a King’s College London spin-out developing small-molecule radiotheranostics for therapy-resistant cancers. The company combines expertise in radiopharmaceutical discovery and clinical translation to advance targeted diagnostic and therapeutic candidates.